Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG) Integrated With Bevacizumab for Patients With Recurrent/Refractory Ovarian Cancer Participating in Study CL-PTL 105
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary) ; Bevacizumab
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Gradalis
- 02 Aug 2017 Status changed from active, no longer recruiting to completed.
- 08 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Oct 2017.
- 08 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Oct 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History